Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Jolly,
LTIP triggered at 25.75...
I reckon staff and execs will go for 45p to maximise
Don't forget the delayed action 3 years
Why wouldn't Angle just go for it around 50p? Then they can raise. Far less dilutitive at those levels so not in the slightest concerned old bean!
Sorry Thompi I misunderstood. I was talking about fairly immediate share price movement. I think all four companies will not be receiving a bid until they are further de-risked. I don't see a buy out for any of them for at least 12 to 18 months. My point is that anybody investing could see a good return on investment as the shares in issue are very reasonable and the prospects are good, and these companies have head room to raise.
I would of course encourage anyone reading this to do their own research and make their own decisions
Hi Thompi,
Shares in issue are 260m so absurd share price spikes are a real possibility to any quality company with good prospects. That includes Angle, OBD, even POLX and RENE could go on a run. And because of sensible share issued, all of these companies have head room to raise if required and still have good runs imo. Investors are looking for the next OBD which hit 55p from 10p levels in late 23. That appears to be Angle in early 24 and I do think it has further to climb again before settling down. Then I guess it will be POLX?
Https://www.lse.co.uk/rns/breakthrough-clinical-results-b0km788ah9aflqm.html
Which led to a 212% spike
Still 70% up a week later
Don’t take my word for it. Explore the list of RNS’s
Here is an example of what examining the WGS with Mext Generation Sequencing can achieve (only if you have a Parsortix device)
https://www.lse.co.uk/rns/breakthrough-clinical-results-b0km788ah9aflqm.html
Sang, I am sure you appreciate that the end users have many different ways of working. Angle has had to become better at matching these differing requirements. Hence the "kits" which are much more challenging to develop than "regular assays" and of course Next Generation Sequencing. Angle have informed the market that they have been engaged in all three in recent month. I think it is more of a case that we as investors are beginning to understand what the company has achieved over the last year or so.
Sang,
The Solaris trial has been fully recruited (100 subjects ) as per webinar Sep 23, and presentations since, and the deck of slides that accompany them, and the company website. We are awaiting results which may take some time, depending on which platform is or will be used to present them. Although there is a MHRA link which shows the trial as being terminated due to low recruitment, I am happy with all the multiple evidence that there are 100 subjects that have provided samples and I will wait.